This article is more than 5 years old. Information may no longer be current.

VIDEO: Similarities seen in PCSK9 inhibitor trials

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LAS VEGAS — In this Cardiology Today video exclusive, Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA, director of the Seinsheimer Cardiovascular Health Program and co-director of women’s heart care at the Medical University of South Carolina in Charleston, discusses two presentations on PCSK9 inhibitors presented at the National Lipid Association Scientific Sessions.

Morris discusses the similarities between the ODYSSEY Outcomes and FOURIER sub-analysis trials, and the implications that they will have on future trials of patients who need PCSK9 inhibitors.

Watch the video for more.